Evidence map›Paper›PMID 31223481›Full record

ArticleBiomarker research2019

Identification of

Yikai Zhang, Ling Xu, Shaohua Chen, Xianfeng Zha, Wei Wei, Yangqiu Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. TCR engineered T cells for solid tumor immunotherapy.Experimental hematology & oncology · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yikai Zhang *1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, 601 Huang Pu Da Dao Xi, 510632 Guangzhou, People's Republic of China.ORCID https://orcid.org/0000-0002-6851-6260
Ling Xu *1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, 601 Huang Pu Da Dao Xi, 510632 Guangzhou, People's Republic of China.
Shaohua Chen1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, 601 Huang Pu Da Dao Xi, 510632 Guangzhou, People's Republic of China.
Xianfeng Zha3Department of Clinical Laboratory, First Affiliated Hospital, Jinan University, Guangzhou, 510632 China.
Wei Wei4Guangzhou Municipality Tianhe Nuoya Bio-engineering Co. Ltd, Guangzhou, 510663 China.
Yangqiu Li1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, 601 Huang Pu Da Dao Xi, 510632 Guangzhou, People's Republic of China.ORCID https://orcid.org/0000-0002-0974-4036
Jinan University · CNFirst Affiliated Hospital of Jinan University · CNHenan Tianguan Group (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously identified a

Indexed as

BCR-ABLChronic myelogenous leukemiaT-cell receptor beta-chain sequencingT cell repertoireWilms tumor 1

Identifiers

PMID31223481
PMCPMC6570921
OpenAlexW2949451120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.